Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

MaRS Investment Accelerator Fund

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 215
Average round size
The average size of a deal this fund participated in
Portfolio companies 186
Rounds per year 15.36
Lead investments 16
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 51
Key employees 7
Stages of investment
Early Stage Venture

Areas of investment

  • Software
  • Enterprise Software
  • Health Care
  • Artificial Intelligence
  • Information Technology

MaRS Investment Accelerator Fund is the famous VC, which was founded in 2007. The company was established in North America in Canada. The main office of represented VC is situated in the Toronto.

We can highlight the next thriving fund investment areas, such as SaaS, Artificial Intelligence. Among the most popular portfolio startups of the fund, we may highlight Top Hat, Fiix Software, Dejero Labs. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada.

The top activity for fund was in 2015. This MaRS Investment Accelerator Fund works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2019. The average startup value when the investment from MaRS Investment Accelerator Fund is 5-10 millions dollars. The common things for fund are deals in the range of 1 - 5 millions dollars. The fund is generally included in 13-24 deals every year. Speaking about the real fund results, this VC is 8 percentage points less often commits exit comparing to other organizations.

The overall number of key employees were 7.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the MaRS Investment Accelerator Fund, startups are often financed by Creative Destruction Lab, Golden Ventures, BDC Venture Capital. The meaningful sponsors for the fund in investment in the same round are BDC Venture Capital, Ontario Centres of Excellence, Extreme Venture Partners. In the next rounds fund is usually obtained by BDC Venture Capital, Ontario Centres of Excellence, iGan Partners.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of MaRS Investment Accelerator Fund:
Typical Co-investors
MaRS Investment Accelerator Fund is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after MaRS Investment Accelerator Fund:

Funds with similar focus

Funds from Canada
Funds with similar focus located in Canada:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Business Intelligence
Health Care
Life Science
Machine Learning
Predictive Analytics
$18M07 Jul 2022 Old Toronto, Ontario, Canada

Basetwo AI

Industrial Automation
Industrial Manufacturing
Predictive Analytics
$3M26 May 2022 Toronto, Ontario, Canada


$2M30 Apr 2022 (Old) Ottawa, Ontario, Canada

Cosm Medical

Health Care
Medical Device
$3M04 Apr 2022 Old Toronto, Ontario, Canada

MedMe Health

Health Care
$2M17 Mar 2022 Old Toronto, Ontario, Canada


$13M10 Feb 2022 Old Toronto, Ontario, Canada


Mapping Services
$1M20 Jan 2022 Old Toronto, Ontario, Canada

Nicoya Lifesciences

Developer Platform
$15M16 Dec 2021 Waterloo, Ontario, Canada


Artificial Intelligence
$1M13 Sep 2021 Ottawa, Ontario, Canada
AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical Trials

– AmacaThera announced the close of an oversubscribed $10.3m Series A financing to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion.
– The Series A round was led by Lumira Ventures and includes a global investor syndicate of existing investors, Viva BioInnovator and Sprout BioVentures, as well as new investors, BDC Capital Women in Technology (WIT) Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures, and MaRS IAF.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MaRS Investment Accelerator Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: